Vitrolife : 6 March 2024, Carnegie Healthcare Seminar Stockholm
March 06, 2024 at 03:42 am EST
Share
Carnegie Healthcare Seminar 2024
Patrik Tolf, CFO
2024-03-06
Mission
Be the leading global partner in reproductive health,
striving for better treatment
outcomes for patients
Global presence in
125
markets
Employees
1,100
Sales in 2023
3,512 MSEK
2
Significant market opportunity in reproductive health
Successful treatment outcomes ~33% ***
1 in 6
134 M
Access and
5-7%
people globally is
babies born annually**
affordability
estimated cycle
affected by infertility*
< 1% via IVF
growth
3
*Source: World Health Organization **Source: United Nations ***ESHRE European mean pregnancy rate in 2019
Corporate Strategy Vitrolife Group
Market
Growth
Labour and
Patient
megatrends
in demand
skills shortage
Consolidation
Regionalisation
empowerment
Our values
Integrity
Quality
Vision with a purpose
"Enable people to fulfil the dream of having a healthy baby"
Mission
"Be the leading global partner in reproductive health, striving for better treatment outcomes for patients"
Long-term growth and profit objectives
Annual organic
EBITDA
Net debt/
revenue growth in
local currencies
margin
EBITDA
>10%
>33%
<3
Innovation
Collaboration
1.
2.
3.
4.
Own the platform
Innovate to expand
Accelerate growth
Optimise go-to-
connecting products
leadership
in key markets
market model
and services
5.
Drive operational
excellence
4
Ensure sustainability in everything we do
Financial highlights 2023
Sales
3,512 MSEK
(3,234 MSEK) +10% in SEK
EBITDA
1,136 MSEK
Margin 32.3% (32.5%)
Organic growth*
Gross margin
+5%
56.3%
In local currencies
(55.0%)
Operating cash flow
Earnings per share**
757 MSEK
3.31 SEK
(636 MSEK)
(2.91 SEK)
* Organic growth excluding discontinued business (Covid testing and GPDx China)
5 ** Adjusted for impairment charge of SEK 4,300 million
Sales and growth per geographical segment, 2023
Organic growth*
Sales (MSEK)
Share of total sales
Americas
EMEA
APAC
Total
-4%
+6%
+15%
+5%
1 159
1 286
1 066
3 512
33%
37%
30%
6
* Organic growth in local currencies
Q&A
DISCLAIMER
This presentation contains estimates and forward-looking statements, which reflect the Management's current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there is no assurance that these statements are correct or will be achieved. The most important strategic and operative risks regarding Vitrolife Group's business and field are described in the Management report, in the Annual Report. These are primarily constituted by macro-economic risks, operational risks and financial risks.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Vitrolife AB published this content on
05 March 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
06 March 2024 08:42:08 UTC.
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Companyâs product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.